Literature DB >> 3000728

Induction of epidermal growth factor-related polypeptides by 17 beta-estradiol in MCF-7 human breast cancer cells.

R B Dickson, K K Huff, E M Spencer, M E Lippman.   

Abstract

MCF-7 human breast cancer cells release polypeptides related to insulin-like growth factor-I (IGF-I) and epidermal growth factor (EGF) into serum-free culture medium (CM). Treatment of MCF-7 cells with 17 beta-estradiol, which is required in vivo for MCF-7 tumor growth in the nude mouse and stimulates the MCF-7 growth rate in vitro, resulted in selectively enhanced growth factor activities in CM. Autostimulatory growth-promoting activity was elevated at least 2-fold, and EGF-like polypeptides were elevated 5-fold but IGF-I immunoreactivity was not elevated. Several species of estrogen-induced receptor-reactive EGF-like polypeptides, suggestive of high molecular weight transforming growth factor alpha, were detected after gel exclusion chromatography of CM extracted with 1 M acetic acid. A 30,000 mol wt peak of EGF receptor competing activity comigrated with a peak of autostimulatory and fibroblast-transforming activity. It is possible that estradiol stimulation of MCF-7 growth and/or tumor formation may depend on induction of EGF-related polypeptide growth factors. EGF-I- and EGF-related polypeptides may act together as autocrine or paracrine growth factors in breast cancer.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3000728     DOI: 10.1210/endo-118-1-138

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  48 in total

Review 1.  Serum-free culture of carcinoma cell lines.

Authors:  P Collodi; C Rawson; D Barnes
Journal:  Cytotechnology       Date:  1991-01       Impact factor: 2.058

2.  Estrogen receptor expression in sporadic vestibular schwannomas.

Authors:  Carrie M Brown; Zana K Ahmad; Allen F Ryan; Joni K Doherty
Journal:  Otol Neurotol       Date:  2011-01       Impact factor: 2.311

3.  Proliferation and differentiation of mouse uterine epithelial cells in primary serum-free culture: estradiol-17 beta suppresses uterine epithelial proliferation cultured on a basement membrane-like substratum.

Authors:  H Fukamachi; J A McLachlan
Journal:  In Vitro Cell Dev Biol       Date:  1991-12

4.  Measurement of occupied and non-occupied epidermal growth factor receptor sites in 216 human breast cancer biopsies.

Authors:  N Falette; M F Lefebvre; F Meggouh; M Eynard; E Garin; S Saez
Journal:  Breast Cancer Res Treat       Date:  1992-03       Impact factor: 4.872

5.  Effects of human breast fibroblasts on growth and 17 beta-estradiol dehydrogenase activity of MCF-7 cells in culture.

Authors:  E F Adams; C J Newton; H Braunsberg; N Shaikh; M Ghilchik; V H James
Journal:  Breast Cancer Res Treat       Date:  1988-05       Impact factor: 4.872

6.  Growth of MTW9/PL2 estrogen-responsive rat mammary tumor cells in hormonally defined serum-free media.

Authors:  D Danielpour; T L Riss; M Ogasawara; D A Sirbasku
Journal:  In Vitro Cell Dev Biol       Date:  1988-01

7.  Solubilization of a tamoxifen-binding protein. Assessment of its molecular mass.

Authors:  A Fargin; J C Faye; M le Maire; F Bayard; M Potier; G Beauregard
Journal:  Biochem J       Date:  1988-11-15       Impact factor: 3.857

8.  MCF-7 breast cancer cells overexpressing transfected c-erbB-2 have an in vitro growth advantage in estrogen-depleted conditions and reduced estrogen-dependence and tamoxifen-sensitivity in vivo.

Authors:  Y Liu; D el-Ashry; D Chen; I Y Ding; F G Kern
Journal:  Breast Cancer Res Treat       Date:  1995-05       Impact factor: 4.872

9.  17-beta-estradiol increases mitogenic activity of medium from cultured preadipocytes of massively obese persons.

Authors:  S C Cooper; D A Roncari
Journal:  J Clin Invest       Date:  1989-06       Impact factor: 14.808

10.  Difference between R5020 and the antiprogestin RU486 in antiproliferative effects on human breast cancer cells.

Authors:  P G Gill; F Vignon; S Bardon; D Derocq; H Rochefort
Journal:  Breast Cancer Res Treat       Date:  1987-10       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.